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ABSTRACT 
Antibiotic resistance is now recognized as a major, global threat to human health and the need for the develop-
ment of novel antibacterial therapies has become urgent. Lytic bacteriophages (phages) targeting individual 
bacterial pathogens have therapeutic potential as an alternative or adjunct to antibiotic use. Bacteriophage 
therapy has been used for decades, but clinical trials in this field are rare, leaving many questions unanswered 
as to its effectiveness for many infectious diseases. As a consequence bacteriophage therapy is not used or 
accepted in most parts of the world. The increasing need for new antimicrobial therapies is driving the devel-
opment of bacteriophage therapies for a number of diseases but these require the successful completion of 
large-scale clinical trials in accordance with US FDA or European EMA guidelines. Bacteriophages are con-
sidered as biological agents by regulatory authorities and they are managed by biological medicinal products 
guidelines for European trials and guidelines of the division of vaccines and related product applications in the 
USA. Bacteriophage therapy is typically an ‘active’ treatment requiring multiplication in the bacterial host and 
therefore the factors that govern its success are different from those of conventional antibiotics. From the phar-
macokinetic and pharmacodynamic points of view, time of treatment, dosage depending on the site of infection 
and the composition of the bacteriophage formulation (single vs multiple strains) need careful consideration 
when designing clinical trials. Scientific evidence regarding inflammatory effects, potential for gene transfer 
and phage resistance, need to be evaluated through such trials. However purity, stability and sterility of prepara-
tions for human use can be addressed through Good Manufacturing Practises to reduce many potential safety 
concerns. In this review we discuss the potential for the development of bacteriophage therapy in the context of 
critical aspects of modern, regulated clinical trials.
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INTRODUCTION
With the rising prevalence of antibiotic resistant-bacte-
ria and the serious concerns raised by the World Health 
Organisation (Levy and Marshall, 2004; Cars et al, 2008; 
WHO 2011), new approaches to deal with bacterial infec-
tions have become an urgent need. Bacteriophage ther-
apy has been applied for decades as a means of treating 
 bacterial  infections in some parts of the world and encour-
aging results have been documented (as reviewed in Kutter 
et al, 2010; Abedon et al, 2011; and described in Marza 
et al, 2006). To date very few human clinical trials have 
been conducted to modern standards in either the European 
Medicines Agency (EMA) or United States FDA jurisdic-
tions. A few phase I studies have been conducted and pub-
lished ( Bruttin and Brüssow, 2005; Merabishvili et al, 2009; 
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Rhoads et al, 2009;) while others have not been published to 
date. In 2009, a US Food and Drug Administration (FDA) 
approved bacteriophage phase I clinical trial was reported, 
evaluating a bacteriophage cocktail targeting Staphylococ-
cus aureus, Pseudomonas aeruginosa and Escherichia coli 
in venous ulcers (Rhoads et al, 2009). The results of this 
trial showed this multi-bacteriophage preparation to be 
safe in trial subjects. Also in 2009, Biocontrol Ltd (UK), 
reported a double-blind placebo-controlled, randomized 
phase I/II clinical trial targeting chronic otitis caused by 
antibiotic-resistant P. aeruginosa. This was the first, and to 
date only, regulated efficacy trial of bacteriophage therapy. 
A positive result was reported showing decreasing levels of 
P. aeruginosa in the ear and improvement of clinical con-
dition with a single input dose of 600,000 bacteriophages 
(Wright et al, 2009). These trials, alongside earlier, less 
well reported studies, indicate that phage therapy shows 
considerable promise for treating infectious diseases caused 
by antibiotic-resistant bacteria.
Despite numerous encouraging case studies, bacteriophage 
treatment has not been brought to mainstream medicine due 
to a lack of robust scientific evidence generated through sys-
tematically planned, controlled and regulated clinical trials. 
Recently, however, an increasing number of papers, reviews 
and books appearing on bacteriophage therapy, as well as 
the emergence of specifically dedicated commercial bacte-
riophage companies indicates an increasing appetite among 
the scientific community and industry for developing bacte-
riophage therapy as part of mainstream medicine (Waldor, 
2005; Górski et al, 2007; Harper and Kutter, 2008; Kutter 
et al, 2010; Burrowes et al, 2011).
Current biomedical technology is vastly superior to that 
available during the early days of bacteriophage therapy. Our 
understanding of the biological properties of bacteriophages 
and the mechanisms of phage-bacterial host interactions has 
also improved dramatically. Although, our knowledge of the 
biology, genetics and bactericidal efficacy of bacteriophages 
in vitro are impressive, less is known about their behaviour 
in vivo, in particular in the human body.
Fully controlled clinical trials under the supervision of ethi-
cal committees and in compliance with the highest regula-
tory standards of leading Western jurisdictions need to be 
performed in order to develop robust, reliable data to answer 
the key clinical questions and to establish the safety and 
efficacy profile of bacteriophage therapy. The gold standard 
will be double blind, randomised controlled trials (RCTs) to 
avoid any bias, and extension to (international) multi-centre 
studies would also be crucial. This will provide the neces-
sary scientific evidence for safe and effective bacteriophage 
therapeutics. Furthermore, comparative studies involv-
ing direct comparison with existing therapies will also be 
needed to answer some of today’s questions.
This review is intended to highlight the critical aspects of reg-
ulated clinical trials in developing bacteriophage therapies. 
REGULATORY CHALLENGES
Bacteriophage therapeutic products have already been mar-
keted in Eastern European countries, such as the Republic of 
Georgia. In Poland, the Ethics Committee of Wroclaw Med-
ical University approved a medical experiment now being 
conducted at the Phage Therapy Unit, a Healthcare Center 
affiliated with the Institute of Immunology and Experimen-
tal Therapy (IIET) in Wroclaw to treat drug-resistant bacte-
rial infections (www.clinicaltrials.gov).
Several other clinical trials and case studies known to use 
bacteriophage therapy have been carried out under different 
jurisdictions. Individual countries have their own regulators, 
and levels of regulation can be highly variable. However, 
the current standard bacteriophage therapies used in Eastern 
Europe are unlikely to receive approval in the rest of Europe 
or USA without further work to prove therapeutic claims 
using regulated clinical trials.
The EMA considers bacteriophages as biological agents 
and although bacteriophage therapy falls under the exist-
ing European regulatory framework on biological medicinal 
products (Commission Directive 2001/83/EC) the directive 
does not fully cover aspects which are specific to bacterio-
phages. However, products such as vaccines (some of which 
are live viruses) that do not have specific regulatory guide-
lines have been approved by EMA and have shown great 
success in mainstream medicine. 
Verbeken et al (2007) argued that bacteriophage should be 
considered as advanced therapy medicinal products (Com-
mission Directive 2003/63/EC), which covers gene therapy, 
somatic cell therapy and tissue engineered products; how-
ever the European Commission has indicated that, as a “bio-
logical”, the existing regulatory framework is adequate for 
bacteriophage therapy. Therefore, the current European reg-
ulation framework on medicinal products may be the way 
forward for bacteriophage therapy in the European Union.
In the US, similar to the situation in Europe, no bacterio-
phage therapeutics guidelines for human use have been pub-
lished by the FDA. Nevertheless, bacteriophage applications 
are handled by the Division of Vaccines and Related Product 
Applications of the Center for Biologicals Evaluation and 
Research (CBER). 
While waiting for bacteriophage therapy to be fitted into 
the regulatory framework, a short term interim solution 
in Europe is to use bacteriophages as a therapy within the 
responsibility and supervision of medical ethical commit-
tees under the umbrella of the World Medical Association 
Declaration of Helsinki (Verbeken et al, 2007; WMA Dec-
laration of Helsinki, 2008). However, this provisional solu-
tion is not a substitute for fully regulated clinical trials and 
consequently fails to move the product forward efficiently.
The FDA and the United States Department of Agriculture 
Food Safety and Inspection Service (USDA, FSIS) cur-
rently recognise commercial bacteriophage preparations 
against common bacterial pathogens such as Listeria mono-
cytogenes and E. coli as safe and approved their use in food 
consumed by humans (71 Fed. Reg. 47729; 2006).
The first bacteriophage-based product formally approved 
by the United States government regulatory agency was 
AgriPhageTM, in 2005 (US EPA 2005), to treat crop  diseases 
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(targeting bacterial speck on crops, with specific formula-
tions for strains of Xanthamonas campestris pv. Vesicato-
ria or P. syringae pv. Tomato). However, the first approved 
food safety-related bacteriophage product was ListShield™ 
(LMP-102™), from Intralytix Inc, a phage cocktail that tar-
gets L. monocytogenes contaminants on ready to eat (RTE) 
foods containing meat and poultry products (Bren, 2007). 
Approval was granted in 2006 and marks the first time that 
the FDA accepted the use of a phage preparation as a food 
additive. Similar food safety applications and other non-
human applications in the agricultural, animal husbandry, 
veterinary and diagnostics sectors appear to be progress-
ing well with an increasing number of products becoming 
available. Such products include AgriPhage, BioTector, 
EcoShield, Finalise, ListShield, LISTEXTM P100 (Monk 
et al, 2010; Ryan et al, 2011). Approval of these products 
should help to support acceptance of the application of bac-
teriophage therapeutics for humans.
However, a serious limitation for small-to-medium scale 
biotech companies seeking to carry out clinical trials is to 
find adequate funding. The lack of regulatory guidelines 
specific to bacteriophage does not currently provide assur-
ance for potential investors that a finished product can be 
licensed (Skurnik et al, 2007). Also, there is little incen-
tive for regulators to develop schemes when no marketed 
product exists. Nevertheless, going forward, the investiga-
tors and sponsors may need to have regular meetings with 
the regulatory agencies to discuss and review the trial strat-
egy alongside the existing regulatory guidelines. It is also 
important to elicit expert knowledge of critical aspects of 
the trial in the absence of published data.
Bacteriophages are naturally occurring organisms. They 
have been used as therapeutic agents for almost a century 
and the basic technology is well established, therefore basic 
concepts are not patentable (Clark and March, 2006). This 
situation is similar to that of monoclonal antibodies, where a 
large number of potential agents exist and the basic technol-
ogy lies in the public domain. However, with monoclonal 
antibodies a number of patent-protected technical devel-
opments, along with the progression of individual agents 
through advanced testing underpin expanding markets 
worth of tens of billions of dollars annually. As with mono-
clonal antibodies, individual bacteriophages are patentable 
since they can be deposited in an approved collection under 
the Budapest treaty (http://www.wipo.int). But, again as 
with monoclonal antibodies, there are always other bacterio-
phages in the environment that may be isolated and used to 
formulate a competing phage preparation. In consequence, 
it is both progression through clinical trials and individual 
technical developments (whether patented or as proprietary 
knowledge) that can underpin the commercialisation of bac-
teriophages, rather than more sweeping patent claims.
Early uses of relatively crude mixtures of antibodies as 
anti-infectives have largely been replaced by more precise 
technologies. Key to this was the ability to purify high lev-
els of individual antibodies. This was achieved by the puri-
fication of individual producer cells, hence the use of the 
term “monoclonal”. Similarly, early bacteriophage prepa-
rations used poorly characterised mixtures, while newer 
work uses high purity, well characterised and fully defined 
 bacteriophages. It is these clonally purified bacteriophages 
that will form the basis of future applications which are 
compliant with regulatory processes. It is perhaps appropri-
ate to refer to these new generation therapeutics by a distinct 
name, perhaps even as “monoclonal bacteriophages” (since 
that is what they actually are) in order to differentiate them 
from earlier approaches.
The practical considerations on the development of regula-
tory compliance in formulations of bacteriophages will be 
discussed in more detail below. 
CLINICAL TRIAL DESIGN CONSIDERATIONS
The trial design aspects of a bacteriophage clinical trial will 
not be vastly different to any other clinical trial design. How-
ever, there are a few unique differences in bacteriophage 
therapy compared to a standard drug or vaccine particularly 
due to its self-replicating ability as well as due to specificity 
of the bacteriophage.
PK/PD data and dose finding
Bacteriophages are typically used as an active (self-repli-
cating) treatment, and more often as a topical rather than 
a systemic treatment. Hence, conventional pharmacokinetic 
(PK) investigational methodologies may not be applicable. 
However, the clinical information on bacteriophage con-
centrations at the site of action and subsequent elimination 
are crucial in designing the dosing schedule when more 
than one dose is deemed necessary. Also, the dose for one 
application (e.g., skin) may not be suitable for another (e.g., 
gastro-intestinal diseases where the bacteriophage need to 
be ingested and act inside the body). The bacteriophage 
concentration at the infection site, bodily distribution and 
rate of clearance (Parisien et al, 2008) of the bacteriophages 
after application will provide useful information for the cli-
nician’s understanding of a given bacteriophage application. 
For an effective treatment, as a rule of thumb, the product 
of the number of bacteriophages (PFU) and the host bacte-
ria (CFU) ranges from 109 to 1011. Thus, for a lower con-
centration of bacteria, a higher number of bacteriophages is 
needed, and vice versa.
From a pharmacodynamics (PD) point of view, efficacy of 
the therapy depends on a few key parameters that are not 
familiar in chemo-based pharmaceutical products (Payne 
et al, 2000). The primary mode of action of bacteriophage 
is bacteriolysis, which requires adsorption of the phage tail 
to a specific receptor on the bacterial cell wall and there 
should be a sufficient number of bacterial cells (prolifera-
tion threshold) for bacteriophages to sustain their numbers 
at the initial stage of the application. Mathematically, num-
ber of encounters between bacteria and bacteriophage in a 
fixed volume of liquid is defined as:
k*t*V*P*N
where, k = adsorption constant; t = time; V = volume; P 
= bacteriophage density (constant); N = bacterial density 
(constant)
This assumes free circulation and does not allow for 
restricted access, bacterial mortality or masking by other 
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have been used in the majority of clinical trials reported 
to date.
Study population 
It is an absolutely critical aspect of a trial to define the 
patient population and the disease stage (acute, chronic, 
etc.) that the final regulatory-approved therapeutic label 
is based upon. If the claim of the bacteriophage therapy is 
associated with treating antibiotic resistant patients with 
chronic disease, the study eligibility criteria should be set 
accordingly. In other words, there should be clear guidelines 
to identify the antibiotic resistant patients who are suffering 
from a specified chronic disease the trial is intended to treat.
Efficacy and safety study parameters
Efficacy
The common efficacy parameters of bacterial infective dis-
ease for registrational trials are of two types:
 • Patient/physician reported outcomes of the patient (typ-
ically primary endpoint)
 • Population dynamics of the infective bacteria (typically 
secondary endpoint)
In addition, bacteriophage population dynamics could also 
be used to complement the above data and provide addi-
tional information on the efficacy of bacteriophage therapy 
(Figure 1). These biological endpoints will be primary in 
pre-clinical or early phase trials. 
Although the patient/physician reported outcomes are of 
high value and reflect the tangible results to the patients it 
is also important to acknowledge the subjectivity in these 
outcomes. Therefore, defining a more profound, clinically 
meaningful quantitative outcome or an objective definition 
for the cure rate for bacteriophage therapy might be an area 
where scientists and clinicians will have to work together to 
provide convincing evidence to the regulatory bodies on the 
performance of bacteriophage therapeutics.
Safety
Safety aspects of the therapy are associated with the potential 
toxicities that can result directly or indirectly and the impact 
on non-target tissues. However, bacteriophage-associated side 
effects are uncommon since bacteriophages and their products 
do not affect eukaryotic cells (Matsuzaki et al, 2005). Although 
claims for safety are supported by the exposure of humans to 
high levels of ubiquitous bacteriophages via everyday activi-
ties (Harper and Enright, 2011), there are at least three safety 
concerns the controlled clinical trials need to consider:
a) The presence of bacterial materials, including toxins, 
pyrogens and other debris (Brüssow et al, 2004). This 
has to be addressed at the bacteriophage preparatory 
stage, and with current technological developments 
a high degree of purity can be achieved at laboratory 
scales (Denou et al, 2009). To address this, bacterio-
phage production for clinical trials under FDA or EMA 
supervision is required to follow specific Good Manu-
facturing Practice (GMP) guidelines with appropriate 
quantity controls (Gill and Hyman, 2010), and to meet 
specific standards for purity and sterility.
substances. The adsorption constant (k), was empirically 
defined by Stent (1963) for T4 Myophage as 2.5x109. It 
appears that it is correlated with the proliferation threshold. 
There are several other mathematical models to describe the 
interaction between bacteriophage and bacteria (Payne and 
Jansen, 2003; Levin and Bull, 2004), however more empiri-
cal data are needed to validate these models.
A number of previous reports (Marza et al, 2006; Wright 
et al, 2009; Hawkins et al, 2010) indicate that a bacterio-
phage count of 102-103 plaque forming unit (PFU) is suffi-
cient to initiate a therapeutic replication with a 106-109 CFU 
per ml proliferation threshold of bacteria in vivo. Trials to 
date have used between 105 and 109 PFU of individual bac-
teriophages (Bruttin and Brüssow, 2005; Merabishvili et al, 
2009; Rhoads et al, 2009; Wright et al, 2009).
Some studies have addressed the issue of the replication 
threshold in vitro; with estimates ranging from 104-106 CFU 
per ml in combination with 102-103 PFU (Wiggins and Alex-
ander, 1985) depending on the experimental situation. This 
is somewhat lower than equivalent numbers in vivo, which 
may reflect the more complex situation in the latter setting. 
At the same time, some researchers deny that a replication 
threshold is relevant (Kasman et al. 2002).
The proliferation onset time (the time required for the bac-
teria to reach proliferation threshold) is another key efficacy 
parameter that influences the success of bacteriophage treat-
ments. However, the timing of treatment is crucial for acute 
infections but is less crucial in chronic infections where 
the infectious bacterial population is found in abundance 
(Maura and Debarbieux, 2011). To combat this problem in a 
clinical trial setting for an acute or premature stage of infec-
tion repeat dosing or use of higher titers of bacteriophages 
may be necessary, as is seen in some animal models of acute 
infections (Debarbieux et al, 2010; Morello et al, 2011).
Workers are thus faced with a range of challenges to provide 
robust clinical data on these efficacy parameters for differ-
ent types of infections when applying for approved bacterio-
phage therapeutics.
Monotherapy vs combination therapy
In standard chemo-therapeutic approaches, mono and com-
bination therapy refers to use of a single drug compared to 
use of multiple drugs at a given time. An analogous treat-
ment strategy exists with bacteriophage when using a sin-
gle bacteriophage compared to the use of a “cocktail” of 
multiple bacteriophage strains. However, use of cocktails as 
a combined therapy poses some challenges in proving the 
specificity or the role of individual viruses. On the positive 
side the cocktails will minimise the disadvantages of bac-
teriophages being specific to a limited number of strains. 
That is to say, in an unknown infection it is more likely 
that a bacteriophage combination therapy will be success-
ful compared to bacteriophage monotherapy with the pos-
sible exception of broad spectrum bacteriophages such as S. 
aureus bacteriophage K (O’Flaherty et al, 2005). Moreover, 
properly selected cocktails can minimise the potential for 
resistance arising in the target bacteria, since one mutation 
could provide resistance to a single phage, no matter how 
broad its spectrum of activity. Unsurprisingly, cocktails 
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According to International Conference on Harmonisation 
(ICH) guideline Q5C (Quality of Biotechnological/Bio-
logical Products) the manufacturer should propose a sta-
bility indicating profile to ensure that changes in identity, 
purity and potency of the product will be detected. The 
same requests will apply to assure the identity, biological 
activity, purity and quality of bacteriophage-drug prod-
ucts when used for humans. In achieving this objective, 
standardization and validation of the techniques used for 
purification, removal of endotoxins and stability should be 
prioritised.
Whether the bacteriophage therapeutic product is a single 
phage with broad specificity or a phage cocktail, it is rec-
ommended that all components in the product should be 
individually characterised (both genomically and pheno-
typically) and analysed. Bacteriophage being a biological 
agent, the natural variations of the organism is an important 
factor to be considered. One of the main reasons for indi-
vidual characterisation is that any possible shifts could be 
detected more easily. 
Therefore in order to achieve a successful therapeutic bac-
teriophage preparation to be used as a clinical product, 
standardisation and specific protocols for the following 
parameters would be very important:
1. Bacteriophage identification 
2.  Potency and biological activity of bacteriophage prep-
arations
3. Product purity
4. Stability and storage conditions of phage preparations
5. Control of sterility
6. Manufacturing process considerations
Suitable identification and monitoring of bacteriophage 
preparations for use in clinical trials is crucial. Each bacte-
riophage should be identified to make sure the preparation 
contains only well-defined bacteriophages. After manu-
facture, to produce the drug substance they can be mixed 
together to produce the bacteriophage cocktail product for 
application (drug product). The product should also be mon-
itored after multiple bacteriophages have been mixed in a 
cocktail product.
All bacteriophage species used in human clinical trials 
should be obligately lytic (virulent) as a minimum require-
ment to ensure the safety of the product. The morpho-
logical types of bacteriophages used should be identified. 
Table 1 summarises the techniques used for characterisa-
tion of high quality bacteriophage preparations for thera-
peutic applications.
Stability and storage of phage preparations
The stability data on bacteriophage-based clinical products 
is important because the preparations must have a shelf-life 
long enough for the duration of the study or to support com-
mercial applications (Withington, 2001). Any change with 
the potential to alter the bacteriophage concentration or pro-
files should be evaluated for its impact on stability. Tem-
perature, pH and buffer/gel compositions are some stability 
parameters. However, the optimal conditions for phage pres-
ervation can vary for each strain. Some  bacteriophages are 
b) The Herxheimer effect due to unusually high levels 
of endotoxins liberated by rapid bacteriolysis or bac-
teriophage-carrying endotoxins. This phenomenon 
was observed with some bactericidal antibiotics (Rac, 
2010) when used to treat severe bacterial infections 
(such as, spirochetal infections) where high numbers of 
bacteria are present. The near-simultaneous lysis of the 
target bacteria can release high levels of toxins (endo-
toxins), produce an autoimmune response to the toxins. 
Despite some concerns (Dixon, 2004) no such phe-
nomenon has been reported with bacteriophages, even 
when this has been the intention of the study (Soothill, 
2004). It is likely that the sequential multiplication of 
bacteriophages produces a longer duration of bacterio-
lytic effect, reducing the effects of such release. How-
ever, this is an area to monitor in trials of bacteriophage 
therapeutics. 
c) The ability of at least some lytic bacteriophages to 
mediate low-level generalised transduction, possibly 
resulting in the transfer of bacterial genes, with the 
potential to result in a more pathogenic or antibiotic-
resistant bacterial hosts (Waddell et al, 2009). From a 
clinical perspective, obligate lytic bacteriophages are 
highly desirable and are generally regarded as safe 
(Burdock and Carabin, 2004). These reduce the poten-
tial for transduction via rapid killing.
Overall, in terms of risk benefit, when viewed in compari-
son with antibiotic treatments where long lasting or serious 
adverse events may occur in some cases (Hamilton, 2011), 
phage therapy may be seen as acceptable (Sulakvelidze et al, 
2001). 
Standardization and quality control of bacteriophage 
therapies
Despite the absence of specific guidelines for therapeutic 
bacteriophage products, in the current medicinal product 
regulations (Verbeken et al, 2007), some of the existing 
requirements for live viral vaccines can be used as a guide 
for bacteriophage-based clinical products. Also, the guide-
lines for biotechnological/biological products, hygiene prod-
ucts and bacteriophage based food-use product approved by 
regulatory agencies can be used as a basis for evaluating 
bacteriophage preparations for therapeutic purposes. 
     Bacteriophage  
    Bacteria  
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um
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Figure 1. Population dynamics of bacteria (CFU) during an 
“active” bacteriophage (PFU) therapy with a single dose of agent. 
Bacteriophage multiplies in vivo, and clears when infection 
resolves.
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growth media composition, conditions of fermentation, fil-
tration methods, purification processes, and the methods 
employed for the evaluation of the bacteriophage prepara-
tions will be important components of the regulatory filing 
for marketing approval.
CONCLUSIONS
Concerns over the increased incidence of antibiotic resist-
ance and lack of effective novel antibiotics have revived 
interest in bacteriophage therapeutics as an approach to con-
trolling bacterial infections. Despite the modern knowledge 
on the genetics and physiology of bacteriophages, there is a 
lack of formal, well-controlled, large scale clinical studies 
on their safety and efficacy as therapeutic agents. Industry 
and regulatory bodies (FDA and EMA) are actively work-
ing towards this goal, using the Biological Medicinal Prod-
ucts guidelines for European trials, and the guidelines of the 
Division of Vaccines and Related Product Applications in 
the USA, as a starting point. 
Standardised protocols to evaluate safe and efficacious bac-
teriophage products are necessary. The mode of action of 
bacteriophage is unique and different to any pharmaceutical 
product in current use. Hence, conventional methodologies 
have little use in understanding many aspects of their use, 
very stable and can be stored in wide-ranging conditions 
while others are fragile and need special attention (Acker-
mann et al, 2004; Merabishvili et al, 2009; Yang et al, 2010; 
Jończyk et al, 2011). If a bacteriophage cocktail is to be 
used in a clinical study, each individual strain should be 
tested. The testing program should define test intervals for 
each storage condition investigated and the tests to be per-
formed at each interval.
Control of sterility
All products to be used in a clinical trial should be sterilized 
by processes that are properly validated. For example, the 
guidelines for sterility testing of biologics are addressed in 
the various worldwide pharmacopeias (e.g., USP, EP and 
JP), Section 21 of the Code of Federal Regulations (CFR), 
ICH and FDA Points to Consider (PTC) documents. The 
same guidelines will need to be applied to test bacterio-
phage preparations.
Manufacturing process considerations
All pharmaceutical products used in clinical trials must be 
manufactured according to GMP guidelines and these are 
equally applicable for bacteriophage formulations in order 
to ensure that bacteriophage products are effective, safe and 
pure. Moreover, all manufacturing process details,  including 
Table 1. Quality parameters of bacteriophage-drug substances and assessment methods
Specification Test Method Acceptance Criteria
Identity
DNA sequencing
Lytic (absence of lysogenic cassettes)
Absence of toxins or other undesirable genes
Transmission electron microscopy with 
negative staining (TEM)
Morphological classification (i.e., Myoviridae, Siphoviri-
dae, Podoviridae).
PCR (primers) can be developed for 
known genes
Absence of transduction (toxins or lysogenic genes); and
taxonomical classification
Host activity and 
Identity
“Cross-plate” technique Phage sensitivity profile compared with standard
Potency (titre)
Agar overlay plaque assay technique
Bacteriophage concentration (titration) of each bacterio-
phage particles (pfu) in a volume of 1ml
Biofilm models vs Plaque assay
Bacteriophage concentration (amplification) in biofilms, 
enhanced in vitro activity in some systems
OD measurement at 600nm
Evaluation of bacterial lysis by measuring the optical den-
sity at 600nm in comparison to control cultures.
DNA fingerprinting 
(Purity)
RFLP, PFGE, PCR, RAPD* RFLP - conformation to reference standards
Protein content 
(residual or host-cell 
protein content)
Protein assays i.e. Bio-Rad Bradford Protein content (>0.7µg/ml)
Protein fingerprinting 
(purity)
SDS-Page** and/or Western blots
Measure relative amounts of protein and reveals proteins of 
interests
Endotoxin
LAL***assay EP <2.6.14>
LAL*** assay USP <85>
<0.5 EU/mg****
Sterility
EP test for sterility <2.6.1>
USP test for sterility <71>
Product sterile
*Restriction fragment length polymorphism (RFLP), Pulsed field gel electrophoresis (PFGE), polymerase chain 
reaction (PCR), random amplified polymorphic DNA (RAPD)
**sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis
***Limulus amoebocyte lysate (LAL) 
****Maximum level of endotoxin for intravenous applications of pharmaceutical and biologic product is set to 5 endotoxin units (EU) 
per kg of body weight per hour by European and US pharmacopoeias.
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